While tremendous strides in prevention and treatment of cancer have been made in recent years, accumulating evidence shows that the costs associated with these advances have led to an increasing financial burden on health-care systems, patients and their families, and society overall ( 1 , 2 ). Medical care costs can often be documented from existing administrative health-care data systems, although other aspects of the financial burden of cancer—particularly, those aspects related to patient costs—are not measured systematically and, as a result, are rarely reported. In this issue of the Journal, Lauzier et al. ( 3 ) add valuable information to our understanding of the financial impact of cancer, describing out-of-pocket expenditures in the first year after treatment initiation among a cohort of women diagnosed with early-stage breast cancer and their spouses from Quebec, Canada. Using multiple measurement time points, the authors detail out-of-pocket costs related to cancer treatment, including those associated with transportation, domestic help, and other accommodations. Lauzier et al. report median net out-of-pocket costs of $1,002 for patients, comprised predominately of costs related to travel, accommodations and management of side effects, and $111 for spouses (2003 Canadian dollars). Further, the authors underscore wage loss as the primary driver of patients’ perceived change for the worse in their family’s financial situation.
Although the authors conclude that out-of-pocket costs for the first year after treatment initiation are probably not unmanageable for most women with early-stage breast cancer, the financial consequences reported likely understate those for breast cancer patients diagnosed with distant metastases and other patients with more treatment-intensive cancers. Additionally, estimates from Canada may not reflect the out-of-pocket costs experienced by cancer patients in the United States or other countries because of fundamental differences in the organization and financing of health care. The magnitude of financial burden on cancer patients can vary widely, especially in the complex US health-care system, which is comprised of multiple payers, coverage policies, annual/lifetime benefit limits and insurance caps, coinsurance, copayments, and deductibles ( 4 ). In addition to costs for transportation and endocrine therapy faced by patients in Quebec, expenses for insured cancer patients in the United States would include deductibles and copayments for hospitalizations, doctor visits, surgical visits, and adjuvant treatments. For cancer patients without health insurance or those who have already reached a lifetime benefit limit, all costs of care would be considered out-of-pocket costs. It is not surprising, then, that a large proportion of US cancer patients and their families report hardship paying their cancer bills ( 5 ), with many families using all or most of their savings ( 6 ).
Moreover, because health insurance in the working-age population is predominantly employer-based in the United States, rather than coverage provided universally as in Canada, maintaining insurance coverage during treatment can be more challenging for patients and their families. Cancer treatment can lead to substantial work loss for both patients and their families, which is manifested as fewer hours worked, change in jobs, or job loss—all of which can lead to a change in or loss of health insurance ( 4 , 7 , 8 ). Time demands associated with cancer treatment may also lead to reduced work and wage loss for patients and caregivers, an indirect cost of cancer care that affects families’ outlook about their financial well-being, as indicated by Lauzier et al. ( 3 ). In the United States, cancer patients may choose to forgo and/or delay recommended medical care, even potentially life-saving cancer treatment, because of an inability to pay or in an attempt to avoid further debt ( 4 , 6 , 9–11 ). Additionally, the decision to forgo or delay care because of cost may be more likely among individuals who are uninsured, low-income, and/or racial/ethnic minorities ( 6 , 9 ), which further perpetuates disparities that lead to poor health outcomes among the most vulnerable populations.
As such, understanding the potential financial consequences of cancer care is increasingly important. Cancer accounts for approximately 5% of total health-care spending in the United States ( 12 ) and 5% to 7% of the health-care budget in Canada ( 13 ). Furthermore, the costs of cancer care in most developed countries are expected to rise because of population growth and aging alone ( 1 , 2 ). Much attention has recently focused on the soaring price of cancer drugs ( 14 ), some with price tags of more than $125 000 per drug per year ( 15 ), often with modest clinical benefits. For US patients facing a coinsurance of 20% to 33% for “top-tier” drugs ( 16 ), this can translate to out-of-pocket costs of approximately $41 000 a year. This phenomenon of patients being exposed to higher costs for expensive cancer medications is becoming more common in Canada as well ( 17 ). Therefore, for both US and Canadian oncologists, consideration of the patient costs associated with cancer treatment will be central to comprehensive discussions with patients and treatment recommendations.
Nevertheless, for providers to be able to have substantive conversations about the costs of cancer treatment with their patients, more studies like that from Lauzier et al. ( 3 ) are needed to provide detailed longitudinal data on patient out-of-pocket costs, including those associated with medical treatment and wage loss. National data, such as the Medical Expenditure Panel Survey Experiences with Cancer Supplement , will provide information about the impact of cancer and its treatment on financial burden, health-care use and expenditures, and the employment of cancer survivors as well as their caregivers ( 18 ). Overall, such evidence on the scope of financial consequences of cancer care for patients and their families, in addition to the clinical benefits and risks, will enhance discussions of the “value” of cancer treatment, which is something oncologists in both the United States and Canada acknowledge as a fundamental component of high-quality care ( 17 , 19 ).
The authors are employees of the National Cancer Institute at the National Institutes of Health and no additional funding was provided specifically for this work.
The authors declare no conflicts of interest.